Paired specimens: An opportunity to answer some important questions

Cancer

Volumn 116, Issue 3, 2010, Pages 574-576

  Haas, Naomi B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CYTOKERATIN AE1; CYTOKERATIN AE3; EPITHELIAL MEMBRANE ANTIGEN; FASCIN; GLUCOSE TRANSPORTER 1; HOMATROPINE METHYL BROMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MELAN A; PROTEIN P53; S6 KINASE; STEM CELL FACTOR; VASCULOTROPIN; VIMENTIN;

CHROMOSOME REARRANGEMENT; CLONAL VARIATION; DIFFERENTIAL DIAGNOSIS; EDITORIAL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RENAL CELL CARCINOMA WITH SARCOMATOID CHANGE; TISSUE SECTION;

CARCINOMA, RENAL CELL; CLONE CELLS; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PHENOTYPE; SARCOMA;

EID: 76249112217     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24778     Document Type: Editorial

References (11)

1. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435-441.
2. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:275-284.
3. Tickoo SK, Alden D, Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1 alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177:1258-1263.
4. Sengupta S, Cheville JC, Corless CL, et al. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol. 2006;175:53-56.
5. Zigeuner R, Droschl N, Tauber V, Rehak P, Langner C. Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Urology. 2006;68:518-522.
6. Figlin RA, Seligson D, Wu H, et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway [abstract]. J Clin Oncol. 2005;23(suppl):387s. Abstract 4539.
7. Kovacs G, Aktar M, Beckwith BJ, et al. The Heidelberg Classification of renal cell tumors. J Pathol. 1997;183:131-133.
8. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987-989.
9. Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002;167:65-70.
10. Shuch B, Said J, LaRochelle JC, et al. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer. 2010;116:616-624.
11. Golshayan AR, George S, Heng D, et al. Metastatic renal cell carcinoma with sarcomatoid component treated with vascular endothelial targeted therapy. J Clin Oncol. 2009; 27:235-241.